Immunotherapy combo shows promise for Hard-to-Treat prostate cancer

NCT ID NCT04717154

Completed Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested two immunotherapy drugs, ipilimumab and nivolumab, in 69 men with a specific type of advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants received four cycles of both drugs, followed by nivolumab alone for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ipilimumab and nivolumab (immunotherapy drugs)
What this could lead to: If successful, this could offer a new treatment option that helps control advanced prostate cancer by using the immune system to fight the disease.
What could go wrong: This is an early-phase trial with only 69 participants, so results may not apply to all patients. Immunotherapy can cause serious side effects like inflammation of organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma Prostatic Neoplasms, Castration-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS, CASTRATION-RESISTANT

Contacts and locations

Locations

Radboudumc

Nijmegen, Gelderland, 6525GA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.